Shareholders Corner - JB Pharma

Close

Investor

Information

Shareholders' Corner

Statutory Disclosures
Other Statutory Disclosures
Code of Conduct

Intimation of Record Date and Date of closure of transfer books

View / Download

Presentation made to Investors – 12.08.2021

View / Download

Disclosure of material event/information – Newspaper Advertisement

View / Download

Grant of Options under Employee Stock Option Scheme

View / Download

Contact details of KMP 04.10.2021

View / Download

Registration/ Log-in details for virtual call with management on 02.03.2021

View / Download

Financial Information

CEO's Desk

We believe that we are BIG enough to create a positive impact for patients and healthcare providers, yet small enough to still care.

Annual Return

List of shareholder 2023

Annual Return as on 31.03.2023

List of shareholders as on 31.03.2022

Annual Return as on 31.03.2022

List of Shareholders as on 31.03.2021

Board Committees

Composition of committees of the board of directors

Business Responsibility Report

Business Responsibility and Sustainability Report 2022-23

Business Responsibility Report 2021-22

Business Responsibility Report 2020-21

Business Responsibility Report 2019-20

Business Responsibility Report 2018-19

Buy-back of Equity Shares

ESOP disclosure for the year ended 31.03.2023

ESOP disclosure for the year ended 31.03.2022

ESOP disclosure for the year ended 31.03.2021

Contact Details of KMP

Contact details of KMP 04.10.2021

CSR Disclosures

CSR Projects FY 2023-24

Annual Report on CSR for the financial year 2022-23

CSR Projects FY 2022-23

Annual Report on CSR for the financial year 2021-22

Composition of CSR Committee

Environmental Compliances

MOEF half yearly Compliance report

ESOP Disclosures

ESOP disclosure for the year ended 31.03.2023

ESOP disclosure for the year ended 31.03.2022

ESOP disclosure for the year ended 31.03.2021

Familiarisation Programme for IDs

Details of Familiarisation Programme for Directors

General Meetings/Postal Ballot

Postal Ballot Notice 06.03.2024

Newspaper advertisment for Postal Ballot FY 2023-24 09.03.2024

Postal Ballot Voting Results 08.04.2024

Postal Ballot Voting Results FY23-24

Newspaper advertisement for Postal Ballot FY23-24

Intimation to Stock Exchanges

Newspaper advertisement of extract of unaudited consolidated financial results for Q3 ended December 31, 2023

Intimation of Record Date for Interim Dividend 2023-24

Intimation of schedule of Analysts/Institutional investors meet

Notice of Board Meeting for Q3 results

Notice of Board Meeting for Q2 results

Letter of Appointment of IDs

Letter of Appointment of IDs

Material Information/Event

Disclosure of Material Event – Disclosure under Regulation 30 of SEBI (LODR) Regulations 24.04.2024

Disclosure of Material Event – Update on appointment of Director 08.04.2024

Disclosure of Material Event – Disclosure under Regulation 30 of SEBI (LODR) Regulations 22.03.2024

Demise of Mr. Ranjit Shahani – Chairman and Independent Director 09.03.2024

Disclosure of Material Event – Allotment of Equity Shares on exercise of Stock options pursuant to ESOP Scheme 05.03.2024

Shareholding Pattern

Statement showing holding of securities and Shareholding pattern – Q4 2023-24

Statement showing holding of securities and shareholding pattern – Q3 2023-24

Statement showing holding of securities and shareholding pattern – Q2 2023-24

Statement showing holding of securities and shareholding pattern – Q1 2023-24

Statement showing holding of securities and shareholding pattern – Q4 2022-23

Subsidiary Companies Financials

Accounts of subsidiary Unique Pharmaceutical Laboratories FZE, Dubai for the year ended on March 31, 2023

Accounts of subsidiary OOO Unique Pharmaceutical Laboratories, Russia for the year ended on March 31, 2023

Accounts of subsidiary Biotech Laboratories (Pty.) Ltd., South Africa for the year ended on March 31, 2023

Accounts of subsidiary Biotech Laboratories (Pty.) Ltd., South Africa for the year ended on March 31, 2022

Accounts of subsidiary OOO Unique Pharmaceutical Laboratories, Russia for the year ended on March 31, 2022

Transfer of shares to IEPF

Statement of shares transferred to IEPF during FY 2023-24

Statement of shares liable for transfer to IEPF during 2023-24

Notice in respect of equity shares liable to transfer to IEPF during 2023-24

Statement of shares transferred to IEPF during FY 2023-24

Notice in respect of equity shares liable to transfer to IEPF during 2023-24

Unclaimed Dividend

Statement of Shareholders for Unclaimed Final Dividend 2021-22 transferred to Unpaid dividend account

Statement of Shareholders for Unclaimed Interim Dividend 2021-22 transferred to Unpaid dividend account

Statement of Shareholders for Unclaimed Final Dividend 2020-21 transferred to Unpaid dividend account

Statement of Shareholders for Unclaimed Interim Dividend 2020-21 transferred to Unpaid dividend account

Unclaimed Dividend as on 31.03.2020

Financial Information

CEO's Desk

We believe that we are BIG enough to create a positive impact for patients and healthcare providers, yet small enough to still care.

Code of practices and procedures for fair disclosure of Unpublished Price Sensitive Information

View / Download

Code of Conduct for Board of Directors and Senior Management Personnel

View / Download

Financial Information

CEO's Desk

We believe that we are BIG enough to create a positive impact for patients and healthcare providers, yet small enough to still care.

IR & Shareholder Contact

For Shareholders: Mr. Sandeep Phadnis Cnergy IT Park, Unit A2, 3rd floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai 400025. India. Tel No. 91-22-2439 5200 / 2439 5500 Fax No. 91-22-2431 5331 / 2431 5334 Email: sandeep.phadnis@jbpharma.com

For transfer/transmission of shares:
Datamatics Business Solutions Ltd. Plot No. B 5, Part B Crosslane, MIDC, Andheri (East), Mumbai SE” 400 093

Contact Person: Mr. Satish Patil
Tel No: (022) 6671 2001-06
Fax No. (022) 6671 2011
Email: investorquery@datamaticsbpm.com

Nodal Officer for the purpose of coordination with IEPF authority: Mr. Sandeep Phadnis Cnergy IT Park, Unit A2, 3rd floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai 400 025. India. Tel No. 91-22-2439 5200/ 2439 5500 Fax No. 91-22-2431 5331 / 2431 5334
Email: sandeep.phadnis@jbpharma.com